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The unprecedented range of treatments now on offer
for varicose veins poses dilemmas, uncertainties and
incentives for both patients and practitioners. The
array of potential treatment combinations, together
with the preferences and motives of both patients and
specialists, creates a complicated matrix of trade-offs
when deciding which to choose. Some of these trade-
offs are widely discussed, while others are more arcane.
There are some stark contrasts between the trade-offs
involved in publicly funded healthcare systems and in
the private sector.
Key issues for patients are the simplicity, complexity
and discomfort of treatment; recovery and aftercare
(including the need for dressings/compression); symp-
tom relief; cosmetic outcome and the cost of treatment,
including considerations of insurance coverage.
For those offering venous interventions, the prime
focus is successful ablation of veins in the short and
longer term. However, this may be tempered by the
attraction of methods which are relatively easy and
quick to use; and by cost minimisation in publicly
funded healthcare systems, or by the desire to maximise
income in the private sector.
It is well known that most of the treatments now
commonly used for ablation of truncal veins produce
good results in the medium term (>90% at three to
four years and probably thereafter). This has been
the main focus of most studies and applies to tradition-
al surgery, endothermal ablation by laser or radiofre-
quency and bioadhesive (cyanoacrylate) glue.1–4
The issue of what adjunctive methods to use for obvi-
ous varicosities – phlebectomies, foam or liquid sclero-
therapy – and whether to use them concomitantly or
sequentially remains somewhat controversial, despite
the available evidence.5–9
Foam sclerotherapy is somewhat less reliable as the
primary treatment for ablation of venous trunks, but
there is evidence that this may matter little to the
patient in terms of quality of life.10,11 Foam allows
treatment of most or all of the obvious veins in a leg
at a single session (notably recurrent varicose veins),
and it is a less costly option than any other method.12
Mechanochemical ablation (MOCA) seeks to capitalise
on the simplicity and low cost of foam sclerotherapy,
while increasing its effectiveness: but there is a paucity
of longer term long evidence, and there are suggestions
that it may not produce outcomes which are quite as
satisfactory as other methods.13,14
Saphenous vein sparing techniques – CHIVA (Cure
conservatrice et Hemodynamique de l’Insuffiscance
Veineuse en Ambulatoire) and ASVAL (Ambulatory
Selective Varicose vein Ablation under Local anesthe-
sia) – are other methods with claimed advantages,
which have been promoted but not yet widely adopted
for treating for varicose veins.15–17
In publicly funded healthcare systems, like the
National Health Service (NHS) in the UK, there is a
perception that treatment of varicose veins is on the
cusp of what should be provided. Despite evidence-
based recommendations from The National Institute
for Health and Care Excellence (NICE) supporting
varicose vein interventions for people with C2s to C6
disease, there are restrictions in much of the UK,
limiting varicose vein treatments to those who have
complications such as lipodermatosclerosis or
ulcers.18 Elsewhere, treatment for uncomplicated vari-
cose veins is typically given low priority, patients are
not normally followed up and there is little or no qual-
ity control: but there is a sense of gratitude from
patients that they have been treated. The endovenous
methods which are used have generally been selected on
a local basis and with a focus on cost minimisation.
This is in contrast to the private sector where patient
experience and cosmetic outcomes are of paramount
importance: and follow-up and patient satisfaction
are key elements of care.
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Treatments provided in the private sector tend to
reflect insurance company reimbursement policies in
different countries so, for example, more endothermal
ablations are done in the UK and the USA, compared
with France where phlebectomies and sclerotherapy
were funded, but endothermal ablation was not reim-
bursed until 2019.19 Both practitioners and patients
may be influenced by the “quick and easy” nature of
foam sclerotherapy compared with phlebectomies.
Careful phlebectomies can be very time-consuming
for the surgeon and a marathon for the patient, but a
predictably good result is obtained without delay.
Foam sclerotherapy is a much quicker and less
demanding treatment for both practitioner and patient;
but the veins often take much longer to resolve
completely; repeat treatment may sometimes be
required: and use of safe volumes of foam typically
dictates treating two legs on separate occasions.
Whether to treat one leg at a time, or both legs at a
single session, is a complex issue. Using foam, two ses-
sions are commonly needed to avoid an excessive dose
of sclerosant foam for veins in both legs. But for other
types of treatment, patients will be influenced by the
extent and duration of the procedure, the recovery and
ability to get back to work and their enthusiasm to “get
it all done” in one session.20 The surgeon’s advice may
be swayed by both clinical and financial considerations.
In Belgium, there has been a sharp increase in bilateral
procedures since a stipulation that only one endother-
mal device will be reimbursed per patient lifetime.19
Another consideration is that the endothermal
methods (laser and radiofrequency) depend on the
use of a generator which needs either to be purchased
at significant expense, or else hired. Cyanoacrylate
glue, which potentially offers significant advantages
to patients (equally good results but with no need for
injection of tumescent anaesthesia and less postopera-
tive compression), currently presents strong financial
disincentives for adoption, for practitioners with
access to a laser or radiofrequency device, because
each glue kit is costly, and also many private insurers
currently will not fund glue treatment (that may
change following recent publication of supportive
NICE guidance)21.
Used skilfully, any of the treatment methods can
provide good results for properly selected patients
with varicose veins. To what extent individual practi-
tioners should be experienced in a range of methods
(and how wide a range) versus having consistent expe-
rience in just one approach is a matter for debate. They
should certainly be able to inform patients well about
their options and the likely outcomes and risks.
Provision of well-informed choice (including an under-
standing of the consequences of no treatment) should
distinguish venous specialists from the influx of
practitioners who advertise and promote a single type
of treatment as the solution for everyone who wants to
be rid of their varicose veins.
The trade-offs in what is involved in having and
providing different treatments, the clinical and cosmet-
ic outcomes and the financial implications for both
patients and practitioners need to be well considered
and transparent. Venous specialists should balance
their personal preferences, the likelihood of an excel-
lent and durable result and offering good value, when
they advise individual patients about their choice of
treatment for varicose veins.
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